Assetmark Inc. Purchases 2,309 Shares of Ascendis Pharma A/S $ASND

Assetmark Inc. increased its position in Ascendis Pharma A/S (NASDAQ:ASND) by 3,346.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,378 shares of the biotechnology company’s stock after buying an additional 2,309 shares during the quarter. Assetmark Inc.’s holdings in Ascendis Pharma A/S were worth $410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its position in Ascendis Pharma A/S by 12.0% during the first quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock valued at $475,970,000 after acquiring an additional 328,278 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at $51,029,000. RA Capital Management L.P. grew its holdings in shares of Ascendis Pharma A/S by 1.7% during the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock valued at $1,602,474,000 after purchasing an additional 168,752 shares during the last quarter. Braidwell LP bought a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $16,632,000. Finally, Driehaus Capital Management LLC raised its position in Ascendis Pharma A/S by 71.6% in the 1st quarter. Driehaus Capital Management LLC now owns 151,829 shares of the biotechnology company’s stock worth $23,664,000 after purchasing an additional 63,333 shares during the period.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. UBS Group reissued a “buy” rating and issued a $307.00 target price (up previously from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Royal Bank Of Canada raised their price target on Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Cantor Fitzgerald lifted their price target on Ascendis Pharma A/S from $203.00 to $254.00 and gave the stock an “overweight” rating in a research note on Monday, October 13th. Finally, Stifel Nicolaus boosted their price objective on Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a “buy” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $249.80.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $197.74 on Friday. The company has a 50 day simple moving average of $201.67 and a two-hundred day simple moving average of $183.19. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $216.45. The company has a market capitalization of $12.20 billion, a price-to-earnings ratio of -38.32 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analysts’ expectations of $163.17 million. On average, analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.